These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9193200)

  • 1. N-methyl-D-aspartate receptor hypofunction in schizophrenia could arise from reduced cortical connectivity rather than receptor dysfunction.
    Hoffman RE; McGlashan TH
    Arch Gen Psychiatry; 1997 Jun; 54(6):578-80. PubMed ID: 9193200
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of N-Methyl-D-Aspartate Receptors in Action-Based Predictive Coding Deficits in Schizophrenia.
    Kort NS; Ford JM; Roach BJ; Gunduz-Bruce H; Krystal JH; Jaeger J; Reinhart RM; Mathalon DH
    Biol Psychiatry; 2017 Mar; 81(6):514-524. PubMed ID: 27647218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia.
    Stahl SM
    CNS Spectr; 2007 Apr; 12(4):265-8. PubMed ID: 17426663
    [No Abstract]   [Full Text] [Related]  

  • 4. Short-term and long-term effects of N-methyl-D-aspartate receptor hypofunction.
    Greene R; Bergeron R; McCarley R; Coyle JT; Grunze H
    Arch Gen Psychiatry; 2000 Dec; 57(12):1180-1; author reply 1182-3. PubMed ID: 11115333
    [No Abstract]   [Full Text] [Related]  

  • 5. Cortical brain dysfunction in early schizophrenia: secondary pathogenetic hierarchy of neuroplasticity, psychopathology and social impairment.
    Hemmingsen R; Madsen A; Glenthøj B; Rubin P
    Acta Psychiatr Scand Suppl; 1999; 395():80-8. PubMed ID: 10225336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia.
    Jadi MP; Behrens MM; Sejnowski TJ
    Biol Psychiatry; 2016 May; 79(9):716-726. PubMed ID: 26281716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can brain rhythms inform on underlying pathology in schizophrenia?
    Whittington MA
    Biol Psychiatry; 2008 Apr; 63(8):728-9. PubMed ID: 18371495
    [No Abstract]   [Full Text] [Related]  

  • 8. Disconnection and cognitive dysmetria in schizophrenia.
    Friston K
    Am J Psychiatry; 2005 Mar; 162(3):429-32. PubMed ID: 15741456
    [No Abstract]   [Full Text] [Related]  

  • 9. Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia.
    Phillips WA; Silverstein SM
    Behav Brain Sci; 2003 Feb; 26(1):65-82; discussion 82-137. PubMed ID: 14598440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excitatory amino acids and schizophrenia.
    Lo CW
    Biol Psychiatry; 1990 Sep; 28(6):552-4. PubMed ID: 2171683
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR; Chen L
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia patients show task switching deficits consistent with N-methyl-d-aspartate system dysfunction but not global executive deficits: implications for pathophysiology of executive dysfunction in schizophrenia.
    Wylie GR; Clark EA; Butler PD; Javitt DC
    Schizophr Bull; 2010 May; 36(3):585-94. PubMed ID: 18835838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia.
    Catts SV; Ward PB; Lloyd A; Huang XF; Dixon G; Chahl L; Harper C; Wakefield D
    Aust N Z J Psychiatry; 1997 Feb; 31(1):17-26. PubMed ID: 9088482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia.
    Coyle JT; Tsai G
    Int Rev Neurobiol; 2004; 59():491-515. PubMed ID: 15006500
    [No Abstract]   [Full Text] [Related]  

  • 15. Schizophrenia and the disconnection hypothesis.
    Friston KJ
    Acta Psychiatr Scand Suppl; 1999; 395():68-79. PubMed ID: 10225335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
    Laruelle M; Kegeles LS; Abi-Dargham A
    Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia.
    Stein H; Barbosa J; Rosa-Justicia M; Prades L; Morató A; Galan-Gadea A; Ariño H; Martinez-Hernandez E; Castro-Fornieles J; Dalmau J; Compte A
    Nat Commun; 2020 Aug; 11(1):4250. PubMed ID: 32843635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal dysfunction and schizophrenia symptoms.
    Freedman R
    Am J Psychiatry; 2007 Mar; 164(3):385-90. PubMed ID: 17329460
    [No Abstract]   [Full Text] [Related]  

  • 19. Ultrastructural plasticity of excitatory synapses.
    Muller D
    Rev Neurosci; 1997; 8(2):77-93. PubMed ID: 9344180
    [No Abstract]   [Full Text] [Related]  

  • 20. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
    Hashimoto K; Fukushima T; Shimizu E; Komatsu N; Watanabe H; Shinoda N; Nakazato M; Kumakiri C; Okada S; Hasegawa H; Imai K; Iyo M
    Arch Gen Psychiatry; 2003 Jun; 60(6):572-6. PubMed ID: 12796220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.